Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+NSCLC

被引：0
|
作者：
Lu, S. [1 ]
Fan, Y. [2 ]
Yu, Y. [3 ]
Dong, X. [4 ]
Li, J. [5 ]
Zhao, J. [6 ]
Tao, S. [7 ]
Chen, M. [7 ]
Chen, Y. [7 ]
Liu, Y. [7 ]
Xu, J. [7 ]
Hu, X. [8 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Dept Med Oncol, Harbin, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Sichuan Canc Hosp, Chengdu, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[7] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[8] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
ROS1+NSCLC; Asian patients; Matching-Adjusted Indirect Comparison;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.02-12
引用
收藏
页码：S679 / S679
页数：1
相关论文
共 50 条
  • [21] Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
    Ion Agirrezabal
    Victoria K. Brennan
    Fabien Colaone
    Suki Shergill
    Helena Pereira
    Gilles Chatellier
    Valérie Vilgrain
    Advances in Therapy, 2022, 39 : 2035 - 2051
  • [22] Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
    Raymond Wong
    Jesse Fishman
    Koo Wilson
    Michael Yeh
    Mohammed Al-Adhami
    Abigail Zion
    Christopher W. Yee
    Lynn Huynh
    Mei Sheng Duh
    Advances in Therapy, 2023, 40 (4) : 1571 - 1589
  • [23] Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
    Maksymowych, Walter P.
    Thom, Howard
    Morup, Michael F.
    Taieb, Vanessa
    Willems, Damon
    Lyris, Nikos
    Gaffney, Karl
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1023 - 1041
  • [24] Comparative effectiveness of secukinumab and etanercept in biologic-naive patients with psoriatic arthritis assessed by matching-adjusted indirect comparison
    Mease, Philip
    Choy, Ernest
    Nash, Peter
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Pricop, Luminita
    Gandhi, Kunal K.
    Jugl, Steffen M.
    Thom, Howard
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2019, 6 (03) : 113 - +
  • [25] A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma
    Mol, Isha
    Hu, Yannan
    Leblanc, Thomas W.
    Cappelleri, Joseph C.
    Chu, Haitao
    Nador, Guido
    Aydin, Didem
    Schepart, Alex
    Hlavacek, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (02) : 199 - 207
  • [26] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    CANCERS, 2020, 12 (12) : 1 - 15
  • [27] Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
    Agirrezabal, Ion
    Brennan, Victoria K.
    Colaone, Fabien
    Shergill, Suki
    Pereira, Helena
    Chatellier, Gilles
    Vilgrain, Valerie
    ADVANCES IN THERAPY, 2022, 39 (05) : 2035 - 2051
  • [28] Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
    Maloney, David G.
    Kuruvilla, John
    Liu, Fei Fei
    Kostic, Ana
    Kim, Yeonhee
    Bonner, Ashley
    Zhang, Yixie
    Fox, Christopher P.
    Cartron, Guillaume
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [29] Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
    David G. Maloney
    John Kuruvilla
    Fei Fei Liu
    Ana Kostic
    Yeonhee Kim
    Ashley Bonner
    Yixie Zhang
    Christopher P. Fox
    Guillaume Cartron
    Journal of Hematology & Oncology, 14
  • [30] Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia
    Davids, Matthew S.
    Telford, Claire
    Abhyankar, Sarang
    Waweru, Catherine
    Ringshausen, Ingo
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2342 - 2351
12345